{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:46:09Z","timestamp":1788306369710,"version":"build-2803163510"},"reference-count":35,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The objective of this study was to compare outcomes between basiliximab and low-dose r-ATG in living donor kidney transplantation recipients with low immunological risk. Patients in the low-dose r-ATG group received 1.5 mg\/kg of r-ATG for 3 days (total 4.5 mg\/kg). Graft survival, patient survival, acute rejection, de novo donor specific antibody (DSA), estimated glomerular filtration rate (e-GFR) changes, and infection status were compared. Among 268 patients, 37 received r-ATG, and 231 received basiliximab. There was no noticeable difference in the graft failure rate (r-ATG vs. basiliximab: 2.7% vs. 4.8%) or rejection (51.4% vs. 45.9%). de novo DSA was more frequent in the r-ATG group (11.4% vs. 2.4%, p = 0.017). e-GFR changes did not differ noticeably between groups. Although most infections showed no noticeable differences between groups, more patients in the r-ATG group had cytomegalovirus (CMV) antigenemia and serum polyomavirus (BK virus) (73.0% vs. 51.9%, p = 0.032 in CMV; 37.8% vs. 15.6%, p = 0.002 in BK), which did not aggravate graft failure. Living donor kidney transplantation patients who received low-dose r-ATG and patients who received basiliximab showed comparable outcomes in terms of graft survival, function, and overall infections. Although CMV antigenemia, BK viremia were more frequent in the r-ATG group, those factors didn\u2019t change the graft outcomes.<\/jats:p>","DOI":"10.3390\/jcm9051320","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T06:41:20Z","timestamp":1588660880000},"page":"1320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0080-176X","authenticated-orcid":false,"given":"Sang Jin","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsoo","family":"Rhu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Yoo","sequence":"additional","affiliation":[{"name":"Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06355, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunga","family":"Kim","sequence":"additional","affiliation":[{"name":"Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06355, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyo Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Berm","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1053\/ajkd.2001.28925","article-title":"Long-term kidney transplant survival","volume":"38","author":"Hariharan","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/tri.12043","article-title":"Selection of induction therapy in kidney transplantation","volume":"26","author":"Hardinger","year":"2013","journal-title":"Transpl. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/j.1600-6143.2011.03754.x","article-title":"Delayed graft function in the kidney transplant","volume":"11","author":"Siedlecki","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/j.transproceed.2013.08.044","article-title":"Monitoring and treatment for BK virus after kidney transplantation","volume":"45","author":"Moon","year":"2013","journal-title":"Transplant. Proc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/cncr.29924","article-title":"A note on the magnitude of hazard ratios","volume":"122","author":"Azuero","year":"2016","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e12977","DOI":"10.1111\/ctr.12977","article-title":"The appropriate dose of thymoglobulin induction therapy in kidney transplantation","volume":"31","author":"Nafar","year":"2017","journal-title":"Clin. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.transproceed.2011.01.035","article-title":"Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up","volume":"43","author":"Laftavi","year":"2011","journal-title":"Transplant. Proc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.transproceed.2018.02.088","article-title":"Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience","volume":"50","author":"Lee","year":"2018","journal-title":"Transplant. Proc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.12659\/AOT.902266","article-title":"The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients","volume":"22","author":"Lee","year":"2017","journal-title":"Ann. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2215\/CJN.00700117","article-title":"Donor-Specific Antibodies in Kidney Transplant Recipients","volume":"13","author":"Zhang","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.trre.2015.12.002","article-title":"Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation\u2014A review","volume":"30","author":"Pascual","year":"2016","journal-title":"Transplant. Rev. (Orlando)"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMc0805714","article-title":"Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction","volume":"359","author":"Brennan","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/TP.0b013e31825a7d1f","article-title":"Antithymocyte globulin induction in living donor renal transplant recipients: Final report of the TAILOR registry","volume":"94","author":"Gaber","year":"2012","journal-title":"Transplantation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e3181cee42f","article-title":"International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation","volume":"89","author":"Kotton","year":"2010","journal-title":"Transplantation"},{"key":"ref_17","first-page":"46","article-title":"Evaluation of diagnostic tests for cytomegalovirus active infection in renal transplant recipients","volume":"39","author":"Franco","year":"2017","journal-title":"J. Braz. Nefrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.transproceed.2007.01.088","article-title":"Real-time PCR assay compared with antigenemia assay for detecting cytomegalovirus infection in kidney transplant recipients","volume":"39","author":"Kim","year":"2007","journal-title":"Transplant. Proc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.transproceed.2011.05.054","article-title":"Clinical usefulness of plasma quantitative polymerase chain reaction assay: Diagnosis of cytomegalovirus infection in kidney transplant recipients","volume":"43","author":"Rhee","year":"2011","journal-title":"Transplant. Proc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1097\/01.TP.0000066807.91219.F7","article-title":"Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation","volume":"75","author":"Kim","year":"2003","journal-title":"Transplantation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.transproceed.2010.02.040","article-title":"The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation","volume":"42","author":"Jung","year":"2010","journal-title":"Transplant. Proc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ndt\/gfu023","article-title":"BK virus infection: An update on diagnosis and treatment","volume":"30","author":"Sawinski","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e31819cc383","article-title":"An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States","volume":"87","author":"Dharnidharka","year":"2009","journal-title":"Transplantation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(18)32091-9","article-title":"Clinical outcomes after ABO-incompatible renal transplantation: A systematic review and meta-analysis","volume":"393","author":"Scurt","year":"2019","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rivera-Sanchez, R., Delgado-Ochoa, D., Flores-Paz, R.R., Garc\u00eda-Jim\u00e9nez, E.E., Espinosa-Hern\u00e1ndez, R., Bazan-Borges, A.A., and Arriaga-Alba, M. (2010). Prospective study of urinary tract infection surveillance after kidney transplantation. BMC Infect. Dis., 10.","DOI":"10.1186\/1471-2334-10-245"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1399-0012.2005.00327.x","article-title":"Urinary tract infections after renal transplantation: A retrospective review at two US transplant centers","volume":"19","author":"Chuang","year":"2005","journal-title":"Clin. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1600-6143.2007.01860.x","article-title":"Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation","volume":"7","author":"Patlolla","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000085892","article-title":"Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: A five-year prospective randomized study","volume":"25","author":"Sheashaa","year":"2005","journal-title":"Am. J. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/ajt.13191","article-title":"Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study","volume":"15","author":"Hellemans","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/01.tp.0000165847.05787.08","article-title":"A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring","volume":"80","author":"Ciancio","year":"2005","journal-title":"Transplantation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1097\/TP.0b013e3181a484d7","article-title":"Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: Application of statistical approaches to reduce bias in observational comparisons","volume":"87","author":"Willoughby","year":"2009","journal-title":"Transplantation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/SLA.0b013e318187d1da","article-title":"A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy","volume":"248","author":"Woodle","year":"2008","journal-title":"Ann. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Grafals, M., Smith, B., Murakami, N., Trabucco, A., Hamill, K., Marangos, E., Gilligan, H., Pomfret, E.A., Pomposelli, J.J., and Simpson, M.A. (2014). Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: A randomized pilot study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104408"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/S0140-6736(16)32187-0","article-title":"Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): An open-label, multicentre, randomised controlled trial","volume":"388","author":"Thomusch","year":"2016","journal-title":"Lancet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/5\/1320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:09:51Z","timestamp":1760364591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/5\/1320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,2]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["jcm9051320"],"URL":"https:\/\/doi.org\/10.3390\/jcm9051320","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,2]]}}}